Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,431 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 1 Interventional

The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency

NCT05734196
View directory record Official record
Conditions
Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy, ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
Up to 1 Year
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Diego, California • Columbus, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Not listed No phase listed Observational

Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

NCT04489251
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Protein Elisa analysis, microRNA analysis, whole exome sequencing
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 1 Interventional

A Phase 1 Study of ADI-001 in B Cell Malignancies

NCT04735471
View directory record Official record
Conditions
Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Interventions
ADI-001, Fludarabine, Cyclophosphamide
Genetic · Drug
Lead sponsor
Adicet Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
10
States / cities
Stanford, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 1 Interventional Results available

A Study of TAS3351 in NSCLC Patients With EGFRmt

NCT05765734
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
TAS3351
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Nashville, Tennessee • Houston, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

NCT03703102
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
KHK4083, Placebo
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Huntington Beach, California • Irvine, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional Results available

Multi-Site Evaluation of Progressive Tinnitus Management

NCT01015781
View directory record Official record
Conditions
Tinnitus
Interventions
Progressive Tinnitus Management, Wait List Control
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
West Haven, Connecticut • Portland, Oregon • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 3 Interventional

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

NCT06119581
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Interventions
LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
87
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 3 Interventional Results available

Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL)

NCT00562965
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
inotuzumab ozogamicin, rituximab, cyclophosphamide, vincristine, prednisone/prednisolone, mitoxantrone, fludarabine, dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
17
States / cities
Mission Hills, California • Evansville, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 23, 2026, 2:51 AM EDT
Not yet recruiting Not applicable Interventional

HIV/HBV/HCV Triple Screening in Primary Care

NCT07031219
View directory record Official record
Conditions
HIV, HBV (Hepatitis B Virus), HCV
Interventions
electronic medical record alert linked to orders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 3 Interventional Results available

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

NCT02915744
View directory record Official record
Conditions
Metastasis, Breast Cancer
Interventions
NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
19
States / cities
Tucson, Arizona • Orange, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy

NCT07186192
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
Educational Intervention, Health Telemonitoring, Questionnaire Administration, Best Practice
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

NCT02027454
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1265744, GSK1265744 matching placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 23, 2026, 2:51 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

NOCISCAN-Lumbar Spine (LS) Clinical Evaluation Study

NCT04015791
View directory record Official record
Conditions
Lumbar Disc Disease
Interventions
NOCISCAN-LS Disc MR Spectroscopy
Other
Lead sponsor
Nocimed, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of R-CHOP + Azacytidine in Diffuse Large B Cell Lymphoma

NCT01004991
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma
Interventions
rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone, azacytidine
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Not applicable Interventional

Effects of Antagonistic Actions in Response to Trauma Exposure

NCT04617769
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Psychoeducation, Exposure
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 60 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 23, 2026, 2:51 AM EDT
Not listed Not applicable Interventional

A Pilot Study to Examine Efficacy of Peer Mentoring in Promoting Medication Adherence Among People Living With HIV/AIDS

NCT02025322
View directory record Official record
Conditions
HIV
Interventions
Peer Mentoring
Behavioral
Lead sponsor
Jury Candelario
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2015 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Results available

Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

NCT04088890
View directory record Official record
Conditions
B-ALL, B-cell Non Hodgkin Lymphoma, DLBCL, Follicular Lymphoma Grade 3B
Interventions
Fludarabine, Cyclophosphamide, CD22 CAR
Drug
Lead sponsor
Matthew Frank
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Active, not recruiting Phase 1 Interventional

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

NCT01430390
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Lymphoma
Interventions
Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma

NCT02748642
View directory record Official record
Conditions
Mild Atopic Asthma
Interventions
BITS7201A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 23, 2026, 2:51 AM EDT
Recruiting Phase 1Phase 2 Interventional

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

NCT05431270
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Mavrostobart (PT199), Tislelizumab, Gemcitabine + nab-Paclitaxel, Docetaxel, Pemetrexed, Gemcitabine, Carboplatin + Pemetrexed, Pembrolizumab + Carboplatin + Pemetrexed
Drug
Lead sponsor
Phanes Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Huntersville, North Carolina • Oklahoma City, Oklahoma • Nashville, Tennessee + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 23, 2026, 2:51 AM EDT
Not listed Not applicable Interventional

Strategy + RehaCom for Memory Rehabilitation in Traumatic Brain Injury (TBI)

NCT04239456
View directory record Official record
Conditions
Traumatic Brain Injury With Loss of Consciousness
Interventions
RehaCom (software)
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 23, 2026, 2:51 AM EDT
Terminated Phase 1 Interventional

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

NCT04464798
View directory record Official record
Conditions
Lymphoma
Interventions
CC-220, Rituximab, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Lake Mary, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 23, 2026, 2:51 AM EDT
Completed Phase 2 Interventional Results available

Bracing and Strengthening for Posterior Tibial Tendon Dysfunction

NCT00756457
View directory record Official record
Conditions
Posterior Tibial Tendon Dysfunction
Interventions
Bracing, Strengthening exercises, Stretching exercises
Device · Other
Lead sponsor
Ithaca College
Other
Eligibility
40 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 23, 2026, 2:51 AM EDT